Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.

Zalba, Sara; Contreras, Ana M; Haeri, Azadeh; Ten Hagen, Timo L M; Navarro, Iñigo; Koning, Gerben; Garrido, María J

Zalba, Sara; Contreras, Ana M; Haeri, Azadeh; Ten Hagen, Timo L M; Navarro, Iñigo; Koning, Gerben; Garrido, María J.

Afiliación

Zalba S; Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain; Laboratory Experimental Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam 3015 GE, The Netherland.
Contreras AM; Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain.
Haeri A; Laboratory Experimental Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam 3015 GE, The Netherland.
Ten Hagen TL; Laboratory Experimental Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam 3015 GE, The Netherland.
Navarro I; Department of Chemistry and Edaphology, University of Navarra, 31008 Pamplona, Spain.
Koning G; Laboratory Experimental Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam 3015 GE, The Netherland. Electronic address: g.koning@erasmusmc.nl.
Garrido MJ; Department of Pharmacy and Pharmaceutical Technology, University of Navarra, 31008 Pamplona, Spain. Electronic address: mgarrido@unav.es.

J Control Release ; 210: 26-38, 2015 Jul 28.

Article en En | MEDLINE | ID: mdl-25998052

Asunto(s)

Antineoplásicos/administración & dosificación; Cetuximab/administración & dosificación; Neoplasias Colorrectales/tratamiento farmacológico; Receptores ErbB/metabolismo; Compuestos Organoplatinos/administración & dosificación; Animales; Antineoplásicos/química; Antineoplásicos/uso terapéutico; Línea Celular Tumoral; Cetuximab/química; Cetuximab/uso terapéutico; Neoplasias Colorrectales/metabolismo; Neoplasias Colorrectales/patología; Femenino; Humanos; Liposomas; Ratones Desnudos; Compuestos Organoplatinos/química; Compuestos Organoplatinos/uso terapéutico; Oxaliplatino; Carga Tumoral/efectos de los fármacos

Palabras clave

1,1'-Dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (PubChem CID: 16212735); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[Maleimide (polyethylene glycol) 2000] (PubChem CID:406950); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[Methoxy (polyethylenglycol)-2000] (PubChem CID: 406952); 3-(2-Pyridyldithio)propionic-acid-N-hydroxysuccinimide-ester (PubChem CID: 100682); Cetuximab; Cholesterol (PubChem CID:5997); Colorectal cancer; EGFR; Fab'; Hydrogenatedphosphatidylcholine (PubChem CID: 94190); Oxaliplatin; Oxaliplatin (PubChem CID: 5310940); Targeted liposomes; Tris(2-carboxyethyl)-phosphine-hydrochloride (PubChem CID: 2734570); ß-Mercaptoethanol (PubChem CID: 1567)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Compuestos Organoplatinos / Neoplasias Colorrectales / Receptores ErbB / Cetuximab / Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2015 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google